Opko Health Inc (OPK)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $1.25B
Last updated: Nov 17, 2026 at 11:06 AM ET
Opko Health Inc (OPK) Stock Forecast
Analysts expect Opko Health (OPK) to earn -$0.25 per share in the fiscal year ending Dec 31, 2026, on revenue of $420.73M. Of 6 analysts, 5 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 1.67, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 83% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 50.0% |
| Buy | 2 | 33.3% |
| Hold | 1 | 16.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 6
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 25.3%.
- Fiscal year ending Dec 31, 2026
- -$0.25
- EPS consensus, revenue $420.73M
- Fiscal year ending Dec 31, 2027
- -$0.34
- EPS consensus, revenue $314.25M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.25 | -$0.26 to -$0.23 | 2 | $420.73M | $418.95M to $423.19M | 4 |
| Dec 31, 2027 | -$0.34 | -$0.35 to -$0.32 | 2 | $314.25M | $246.70M to $570.30M | 6 |
Quarterly Estimates
The EPS consensus falls from -$0.07 for the quarter ending Dec 31, 2026 to -$0.11 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.07 | -$0.11 to -$0.05 | 7 | $81.64M | $64.68M to $154.56M | 7 |
| Mar 31, 2027 | -$0.11 | -$0.11 to -$0.11 | 1 | $80.28M | $59.30M to $135.80M | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.22.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.25 | -$0.21 | -$0.22 | -$0.22 | -$0.22 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.34 | -$0.34 | -$0.28 | -$0.28 | -$0.28 | N/A |
| Quarter ending Mar 31, 2027 | -$0.11 | -$0.08 | -$0.08 | -$0.08 | -$0.08 | N/A |
Frequently Asked Questions About OPK
What is the OPK stock forecast?
Consensus analyst estimates put Opko Health's EPS at -$0.25 for the fiscal year ending Dec 31, 2026, on revenue of $420.73M. The consensus rating from 6 analysts is Buy.
How do analysts rate OPK stock?
Of 6 analysts covering Opko Health, 3 rate it Strong Buy, 2 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from OPK next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.25, with estimates from -$0.26 to -$0.23 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.34, with estimates from -$0.35 to -$0.32 from 2 analysts.
What revenue do analysts expect from Opko Health next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $420.73M, with estimates from $418.95M to $423.19M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $314.25M, with estimates from $246.70M to $570.30M.
How many analysts cover OPK?
6 analysts rate Opko Health stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
OPK pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts